Insider Shareholders with Direct Ownership of Yumanity Therapeutics, Inc. (YMTX)
This section provides a comprehensive overview of the insiders with direct ownership of Yumanity Therapeutics, Inc. (YMTX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
YUMANITY THERAPEUTICS, INC. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Novartis Bioventures Ltd
> 10% Shareholder |
1,873,791 | 0 | 1,873,791 $0 | 1 |
Feb 17, 2016
Added 16.68%
|
| 922,868 | 922,868 | 860,377 $0 | 11 |
Jun 23, 2025
Reduced 5.74%
|
|
|
N Anthony Coles
Executive Chair |
691,008 | 0 | 691,008 $0 | 2 |
Feb 01, 2021
Added 0.16%
|
|
Craig W. Philips
President and Secretary |
360,880 | 360,880 | 298,464 $0 | 11 |
Jun 25, 2025
Added 16.81%
|
|
Paulash Mohsen
Chief Business Officer |
61,093 | 1,958 | 59,135 $0 | 4 |
Feb 03, 2022
Reduced 3.2%
|
| 35,706 | 35,706 | 31,000 $0 | 12 |
Jun 25, 2025
Added 16.22%
|
|
|
Ajay Verma
EVP, Head of R&D |
30,000 | 0 | 30,000 $0 | 1 |
Dec 01, 2021
Added 50.0%
|
|
Pauline Kenny
General Counsel & Secretary |
20,617 | 2,169 | 18,448 $0 | 5 |
Sep 20, 2023
Added 7.52%
|
|
Michael D Wyzga
Officer |
20,000 | 6,003 | 13,997 $0 | 3 |
Dec 02, 2022
Reduced 18.21%
|
|
Devin Whittemore Smith
SVP and General Counsel |
20,000 | 6,039 | 13,961 $0 | 3 |
Dec 02, 2022
Reduced 18.25%
|
|
Jeffery W. Kelly
Director |
8,117 | 0 | 13,237 $0 | 2 |
Feb 01, 2021
Added 12.89%
|
|
Marie Epstein
Principal Accounting Officer |
12,665 | 3,782 | 8,883 $0 | 3 |
Dec 02, 2022
Reduced 18.2%
|
|
Richard A. Heyman
Director |
8,117 | 0 | 8,117 $0 | 2 |
Feb 01, 2021
Added 19.44%
|
|
Cecil B Pickett
Director |
8,117 | 0 | 8,117 $0 | 2 |
Feb 01, 2021
Added 19.44%
|
| 22,847 | 21,277 | 0 $0 | 5 |
Jun 30, 2025
Reduced 100.0%
|
|
| 149,443 | 149,443 | 0 $0 | 13 |
Jun 30, 2025
Reduced 100.0%
|
|
| 169,862 | 169,862 | 0 $0 | 7 |
Jun 30, 2025
Reduced 100.0%
|
|
| 18,500 | 18,500 | 0 $0 | 4 |
Jun 30, 2025
Reduced 100.0%
|
|
|
Thierry Guillaudeux
Chief Scientific Officer |
269,796 | 264,980 | 0 $0 | 6 |
Jun 30, 2025
Reduced 100.0%
|
|
Keith Baker
Chief Financial Officer |
295,580 | 295,580 | 0 $0 | 7 |
Jun 30, 2025
Reduced 100.0%
|
| 36,294 | 4,706 | 0 $0 | 4 |
Jun 30, 2025
Added 100.0%
|